156 related articles for article (PubMed ID: 35920616)
1. Efficacy and safety of phosphatidylinositol 3-kinase inhibitors in patients with chronic lymphocytic leukemia: a meta-analysis and systematic review.
Wen Y; Meng L; Zhang X; Gao Q
Expert Rev Hematol; 2022 Sep; 15(9):849-856. PubMed ID: 35920616
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials.
Wang Z; Zhou H; Xu J; Wang J; Niu T
Front Immunol; 2022; 13():1070660. PubMed ID: 36685572
[TBL] [Abstract][Full Text] [Related]
3. The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.
Lampson BL; Brown JR
Hematol Oncol Clin North Am; 2021 Aug; 35(4):807-826. PubMed ID: 34174987
[TBL] [Abstract][Full Text] [Related]
4. Exploring a Future for PI3K Inhibitors in Chronic Lymphocytic Leukemia.
Patel K; Pagel JM
Curr Hematol Malig Rep; 2019 Aug; 14(4):292-301. PubMed ID: 31203516
[TBL] [Abstract][Full Text] [Related]
5. Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?
Aydin E; Faehling S; Saleh M; Llaó Cid L; Seiffert M; Roessner PM
Front Immunol; 2020; 11():595818. PubMed ID: 33552053
[TBL] [Abstract][Full Text] [Related]
6. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
Wiestner A
Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
[TBL] [Abstract][Full Text] [Related]
7. Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma.
Brown JR; Davids MS; Rodon J; Abrisqueta P; Kasar SN; Lager J; Jiang J; Egile C; Awan FT
Clin Cancer Res; 2015 Jul; 21(14):3160-9. PubMed ID: 25840972
[TBL] [Abstract][Full Text] [Related]
8. Phosphoinositide 3'-kinase inhibition in chronic lymphocytic leukemia.
Davids MS; Brown JR
Hematol Oncol Clin North Am; 2013 Apr; 27(2):329-39. PubMed ID: 23561476
[TBL] [Abstract][Full Text] [Related]
9. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.
Xu W; Yang S; Zhou K; Pan L; Li Z; Zhou J; Gao S; Zhou D; Hu J; Feng R; Huang H; Ji M; Guo H; Huang J; Novotny W; Feng S; Li J
J Hematol Oncol; 2020 May; 13(1):48. PubMed ID: 32393328
[TBL] [Abstract][Full Text] [Related]
10. PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here?
Skånland SS; Brown JR
Haematologica; 2023 Jan; 108(1):9-21. PubMed ID: 35899388
[TBL] [Abstract][Full Text] [Related]
11. Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis.
Wang S; Liu M; Lian S; Liu N; Zhang G; Zhao Q; Zhang Y; Jian L
Biomed Res Int; 2020; 2020():7451576. PubMed ID: 33376736
[TBL] [Abstract][Full Text] [Related]
12. Metabolic and toxicological considerations for phosphoinositide 3-kinase delta inhibitors in the treatment of chronic lymphocytic leukemia.
Witkowska M; Majchrzak A; Robak P; Wolska-Washer A; Robak T
Expert Opin Drug Metab Toxicol; 2023 Sep; 19(9):617-633. PubMed ID: 37714711
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of B-cell receptor signaling pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized clinical trials.
Puła A; Stawiski K; Braun M; Iskierka-Jażdżewska E; Robak T
Leuk Lymphoma; 2018 May; 59(5):1084-1094. PubMed ID: 28891366
[TBL] [Abstract][Full Text] [Related]
14. IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia.
Assouline S; Amrein L; Aloyz R; Banerji V; Caplan S; Owen C; Hasegawa W; Robinson S; Shivakumar S; Prica A; Peters A; Hagerman L; Rodriguez L; Skamene T; Panasci L; Chen BE; Hay AE
Leuk Lymphoma; 2020 Jul; 61(7):1653-1659. PubMed ID: 32154751
[TBL] [Abstract][Full Text] [Related]
15. The impact of immune checkpoint inhibitors in patients with chronic lymphocytic leukemia (CLL): A protocol for a systematic review and meta-analysis of randomized controlled trials.
Ntsethe A; Dludla PV; Nyambuya TM; Ngcobo SR; Nkambule BB
Medicine (Baltimore); 2020 Jul; 99(28):e21167. PubMed ID: 32664154
[TBL] [Abstract][Full Text] [Related]
16. Risk of cutaneous adverse events in cancer patients treated with phosphatidylinositol-3-kinase inhibitors: A systematic review and meta-analysis of randomized controlled trials.
Wang Y; Ma Z; An Z; Zhang Y; Feng X; Yu X
Cancer Med; 2023 Feb; 12(3):2227-2237. PubMed ID: 35986570
[TBL] [Abstract][Full Text] [Related]
17. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
18. Duvelisib (Copiktra) in relapsed or refractory chronic lymphocytic leukemia: safety and efficacy.
Nikolaenko L; Liu T; Danilov AV
Expert Rev Anticancer Ther; 2021 May; 21(5):481-488. PubMed ID: 33499685
[No Abstract] [Full Text] [Related]
19. Randomized controlled trials in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis.
Police RL; Trask PC; Wang J; Olivares R; Khan S; Abbe A; Colosia A; Njue A; Sherrill B; Ruiz-Soto R; Kaye JA; Hamadani M
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):199-207. PubMed ID: 25445467
[TBL] [Abstract][Full Text] [Related]
20. Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors.
Hanlon A; Brander DM
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):346-356. PubMed ID: 33275709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
